CT-322: A New Treatment for Pancreatic Cancer
Author Information
Author(s): Sean P Dineen, Laura A Sullivan, Adam W Beck, Andrew F Miller, Juliet G Carbon, Roni Mamluk, Henry Wong, Rolf A Brekken
Primary Institution: University of Texas Southwestern Medical School
Hypothesis
Can CT-322 effectively inhibit tumor growth and angiogenesis in pancreatic cancer models?
Conclusion
CT-322 is an effective anti-VEGFR2 agent that warrants further investigation for treating pancreatic cancer.
Supporting Evidence
- CT-322 reduced pancreatic tumor growth by approximately 50% in the xenograft model.
- CT-322 treatment increased apoptosis and reduced microvessel density in tumors.
- The combination of CT-322 and gemcitabine was effective in controlling tumor growth.
Takeaway
CT-322 is a new medicine that helps stop pancreatic cancer from growing by blocking a protein that helps tumors get blood.
Methodology
The study used two orthotopic pancreatic tumor models in mice to evaluate the efficacy of CT-322.
Limitations
The study was conducted in animal models, which may not fully represent human responses.
Participant Demographics
The study involved athymic nude mice and C57BL/6J wild-type mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website